Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Assessment of absorption potential of poorly water-soluble drugs by using the dissolution/permeation system.

Kataoka M, Yano K, Hamatsu Y, Masaoka Y, Sakuma S, Yamashita S.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1317-24. doi: 10.1016/j.ejpb.2013.06.018.

PMID:
23811221
2.
3.

Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.

Kataoka M, Sugano K, da Costa Mathews C, Wong JW, Jones KL, Masaoka Y, Sakuma S, Yamashita S.

Pharm Res. 2012 Jun;29(6):1485-94. doi: 10.1007/s11095-011-0623-2.

PMID:
22134778
4.

In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs.

Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S.

Pharm Res. 2003 Oct;20(10):1674-80.

PMID:
14620525
5.

Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.

Kataoka M, Fukahori M, Ikemura A, Kubota A, Higashino H, Sakuma S, Yamashita S.

Eur J Pharm Biopharm. 2016 Apr;101:103-11. doi: 10.1016/j.ejpb.2016.02.002.

PMID:
26873006
6.

Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.

Nasr M.

AAPS PharmSciTech. 2013 Jun;14(2):719-26. doi: 10.1208/s12249-013-9957-x.

7.

Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation.

Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S.

Pharm Res. 2008 Oct;25(10):2334-44. doi: 10.1007/s11095-008-9637-9.

PMID:
18560998
8.

Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.

Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S.

Pharm Res. 2006 Jun;23(6):1144-56.

PMID:
16715363
9.

Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.

Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB.

Eur J Pharm Biopharm. 2009 Sep;73(1):107-14. doi: 10.1016/j.ejpb.2009.05.009.

PMID:
19465123
10.

Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.

Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF.

J Pharm Sci. 2007 Oct;96(10):2686-702.

PMID:
17518357
11.

An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs.

He X, Sugawara M, Kobayashi M, Takekuma Y, Miyazaki K.

Int J Pharm. 2003 Sep 16;263(1-2):35-44.

PMID:
12954178
12.

In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.

Song WH, Yeom DW, Lee DH, Lee KM, Yoo HJ, Chae BR, Song SH, Choi YW.

Arch Pharm Res. 2014 May;37(5):626-35. doi: 10.1007/s12272-013-0202-7.

PMID:
23852645
13.
14.
15.

IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

Buch P, Langguth P, Kataoka M, Yamashita S.

J Pharm Sci. 2009 Jun;98(6):2001-9. doi: 10.1002/jps.21576.

PMID:
18855916
16.

Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.

Miyaji Y, Fujii Y, Takeyama S, Kawai Y, Kataoka M, Takahashi M, Yamashita S.

Mol Pharm. 2016 May 2;13(5):1564-74. doi: 10.1021/acs.molpharmaceut.6b00044.

PMID:
27031624
17.

In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.

Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C.

Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019.

PMID:
23727464
18.

A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib.

Zhang Y, Wang H, Li C, Sun B, Wang Y, Wang S, Gao C.

Pharm Res. 2014 Apr;31(4):1059-70. doi: 10.1007/s11095-013-1227-9.

PMID:
24287624
19.

Integrating drug permeability with dissolution profile to develop IVIVC.

Takano R, Kataoka M, Yamashita S.

Biopharm Drug Dispos. 2012 Oct;33(7):354-65. doi: 10.1002/bdd.1792. Review.

PMID:
22581486
20.
Items per page

Supplemental Content

Support Center